


Claims

1. Use of finerenone or a hydrate, solvate, pharmaceutically acceptable salt thereof, or a polymorph thereof in the manufacture of a medicament for preventing or treating chronic kidney disease in a patient with type I diabetes, wherein the finerenone or a hydrate, solvate, pharmaceutically acceptable salt thereof, or a polymorph thereof is to be administered to the patient in a therapeutically effective amount thereof.
2. Use of finerenone or a hydrate, solvate, pharmaceutically acceptable salt thereof, or a polymorph thereof in the manufacture of a medicament for delaying the progression of chronic kidney disease in a patient with chronic kidney disease associated with type 1 diabetes, wherein the medicament is to be administered to the patient in a therapeutically effective amount thereof.
3. Use of finerenone or a hydrate, solvate, pharmaceutically acceptable salt thereof, or a polymorph thereof in the manufacture of a medicament for reducing the risk of sustained UACR decline in a patient with chronic kidney disease associated with type 1 diabetes, wherein the medicament is to be administered to the patient in a therapeutically effective amount thereof, optionally wherein prior to receiving finerenone.
4. The use according to any one of claims 1 to 3, wherein prior to the medicament being administered, the patient has
 - (1) albuminuria,
 - (2) a UACR of equal to or above 150, 200, 250, 300, 350, 400, 450 or 500 mg/g, and/or
 - (3) a UACR of 30 to 5000, 200 to 5000, 200 to 4000, 200 to 3000, or 200 to 2000 mg/g.
5. The use according to any one of claims 1 to 4, wherein prior to the medicament being administered, the patient has a UACR of
 - (1) equal to or below 200 mg/g, or
 - (2) equal to or above 200 mg/g, or
 - (3) equal to or below 300 mg/g, or
 - (4) equal to or above 300 mg/g, or
 - (5) 300 to 1000 mg/g, or
 - (6) equal to or below 1000 mg/g, or
 - (7) equal to or above 1000 mg/g, or
 - (8) 200 to 5000 mg/g, or
 - (9) 200 to 1000 mg/g, or
 - (10) equal to or below 5000 mg/g.

6. The use according to any one of claims 1 to 5, wherein prior to the medicament being administered, the patient has
 - (1) an eGFR of equal to or above 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, or 75 mL/min/1.73 m², or
 - (2) an eGFR of from 15-90, 20-90, 25-90, 30-90, 60-90, 25-75, or 25-60 mL/min/1.73 m².
7. The use according to any one of claims 1 to 6, wherein prior to the medicament being administered, the patient has an eGFR of
 - (1) equal to or below 25 mL/min/1.73 m², or
 - (2) equal to or above 25 mL/min/1.73 m², or
 - (3) equal to or below 45 mL/min/1.73 m², or
 - (4) equal to or above 45 mL/min/1.73 m², or
 - (5) 45 to 60 mL/min/1.73 m², or
 - (6) 45 to 90 mL/min/1.73 m², or
 - (7) 25 to 60 mL/min/1.73 m², or
 - (8) 25 to 90 mL/min/1.73 m², or
 - (9) equal or below 60 mL/min/1.73 m², or
 - (10) equal or above 60 mL/min/1.73 m², or
 - (11) equal or below 90 mL/min/1.73 m².
8. The use according to any one of claims 1 to 7, wherein prior to the medicament being administered, the patient has a UACR of 200 to 5000 mg/g, an eGFR of 25 to <90 mL/min/1.73 m², and has been administered a stable dosage of an ACEI or ARB for >4 weeks.
9. The use according to any one of claims 1 to 8, wherein prior to initiation of finerenone therapy, the patient has been administered a stable dosage of an ACEI or ARB.
10. The use according to any one of claims 1 to 9, wherein the patient is not to be co-administered one or more additional therapeutic agents selected from the group consisting of an SGLT2 inhibitor, an GLP1 receptor agonist, and a mineralocorticoid receptor antagonist other than finerenone.
11. The use according to any one of claims 1 to 10, wherein the patient is to be administered finerenone at a daily dosage selected from the group consisting of 7.5 mg, 10 mg, 20 mg, 40 mg, a range of 10 mg to 20 mg, and a range of 10mg to 40mg.

12. The use according to any one of claims 1 to 11, wherein the patient is to be administered finerenone in a daily amount of 0.25 mg to 80 mg.
13. The use according to any one of claims 1 to 12, wherein the finerenone is a compound of the formula (I) in crystalline form of polymorph I



- wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 8.5, 14.1, and 19.0.
14. The use according to any one of claims 1 to 12, wherein the finerenone is the compound of formula (I) in crystalline form of polymorph, wherein the x-ray diffractogram of the compound further exhibits any of peak maxima of the 2 theta angle at 17.2, 20.5, 25.6, and 26.5.
15. The use according to any one of claims 1 to 12, wherein the finerenone is the compound of the formula (I) in crystalline form of polymorph I according to claim 14, wherein the IR spectrum of the compound exhibits any one of band maxima at 3475, 2230, 1681, 1658, 1606, 1572, 1485, 1255, 1136 and 1031 cm^{-1} .